Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 1056 clinical trials
Study of CBX-12 in Subjects With Advanced or Metastatic Refractory Solid Tumors

This is a first-in-human, Phase 1/2 open-label, multicenter, dose-escalation, safety, pharmacokinetics (PK), and biomarker study of CBX-12 in subjects with advanced or metastatic refractory solid tumors.

systemic therapy
core needle biopsy
measurable disease
  • 0 views
  • 30 May, 2022
  • 4 locations
A Study of KF-0210 in Advanced Solid Tumors Patients

The purpose of this Phase I, Multi-Center, Open-Label Study is to evaluate the safety, tolerability, Pharmacokinetics, Pharmacodynamics and anti-tumor activity of KF-0210 in participants with advanced solid tumors. The study will be conducted in two parts: phase Ia, and phase Ib.

measurable disease
atezolizumab
  • 5 views
  • 11 Sep, 2021
  • 1 location
Phase 1a/1b Study of STK-012 Monotherapy and in Combination With Pembrolizumab in Patients With Solid Tumors

This is a first-in-human, phase 1a/1b, multicenter, open-label, dose escalation study of STK-012 as monotherapy and in combination with pembrolizumab in patients with selected advanced solid tumors.

interleukin 2
monoclonal antibodies
pembrolizumab
interleukin-2
  • 0 views
  • 04 Oct, 2022
  • 4 locations
GI-101 as a Single Agent or in Combination With Pembrolizumab, Lenvatinib or Local Radiotherapy in Advanced Solid Tumors

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and therapeutic activity of GI-101 as a single agent or in combination with pembrolizumab, lenvatinib or local radiotherapy (RT) over a range of advanced and/or metastatic solid tumors.

alopecia
lenvatinib
cancer chemotherapy
cancer
HIV Infection
  • 0 views
  • 02 May, 2022
  • 4 locations
Inovio TRT-001: Telomerase DNA Immunotherapy in Breast Lung and Pancreatic Cancers

This is a Phase I, open label study to evaluate the safety, tolerability, and immunogenicity of INO-1400 alone or in combination with INO-9012, delivered by electroporation in subjects with high risk breast, lung, or pancreatic cancer with no evidence of disease after surgery and adjuvant therapy. Subjects will be enrolled …

adjuvant therapy
pancreatic cancers
cancer
  • 72 views
  • 07 Nov, 2020
  • 3 locations
Study of NEO-201 in Solid Tumors Expansion Cohorts

The open label, first-in-human, phase 1, dose escalation component in refractory solid tumors has been completed. The Maximum Tolerated Dose and Recommended Phase 2 Dose (RP2D) was determined to be 1.5mg/kg. The Expansion Phase of this study is currently enrolling subjects with non small cell lung cancer (NSCLC), head and …

neutrophil count
ROS1
proto-oncogene tyrosine-protein kinase ros
ovarian cancer
EGFR
  • 45 views
  • 23 Apr, 2022
  • 1 location
PLATON - Platform for Analyzing Targetable Tumor Mutations (Pilot-study) (PLATON)

PLATON (Platform for Analyzing Targetable Mutations) is a prospective, multicentre, observational cohort study with biobanking. In a first approach PLATON's pilot-study assesses genomic profiling in gastrointestinal cancer therapy and the frequencies of targetable mutations including Tumor Mutational Burden (TMB) and Microsatellite Instability Status (MSI), performing Next-generation deep sequencing (NGS) using …

adenocarcinoma
breast ductal carcinoma
gastrointestinal cancer
cancer
pancreatic ductal adenocarcinoma
  • 0 views
  • 04 Oct, 2022
  • 30 locations
A Phase 1, Open-Label, Multi-Center, Dose Escalation and Expansion Study of HFB200301 (TNFR2 Agonist Antibody) in Adult Patients With Advanced Solid Tumors

The purpose of this study is to test the safety and tolerability of HFB200301 in patients with advanced cancers. There are two parts in this study. During the escalation part, groups of participants will receive increasing doses until a safe and tolerable dose of HFB200301 is determined. During the expansion …

BRAF
lung carcinoma
cancer
lung cancer
systemic therapy
  • 0 views
  • 21 Oct, 2022
  • 10 locations
A Study of [225Ac]-FPI-1966 in Participants With Advanced Solid Tumours

This is a first-in-human, Phase 1/2, non-randomized, multi-centre, open-label clinical study designed to investigate safety, tolerability, dosimetry, biodistribution, and PK of [225Ac] FPI-1966, [111In]-FPI-1967, and vofatamab and the preliminary anti-tumour activity of [225Ac]-FPI-1966 in participants with FGFR3-expressing advanced, inoperable, metastatic, and/or recurrent solid tumours. Phase 1 consists of five multiple …

FGFR3
growth factor
renal function
monoclonal antibodies
immunohistochemistry
  • 1 views
  • 04 Oct, 2022
  • 1 location
Study Evaluating GZ17-6.02 in Patients With Advanced Solid Tumors or in Combination With Capecitabine in Metastatic Hormone Receptor Positive Breast Cancer (GEN602)

This Phase I/Ib study is a Multicenter, Open-label, Dose-Escalation, Safety, Pharmacodynamic and Pharmacokinetic Study of GZ17-6.02 Monotherapy and in Combination with Capecitabine, Given Orally on a Daily Schedule in Patients with Advanced Solid Tumors or Lymphoma

gz17-6.02
fasting
coagulants
capecitabine
estrogen
  • 40 views
  • 23 May, 2022
  • 1 location